Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Positive NCX 470 pre-submission regulatory feedback in China
June 18, 2026
What is the news ?
Nicox announces that its Chinese partner Ocumension Therapeutics received positive pre-submission feedback from the Chinese Center for Drug Evaluation (CDE), supporting the filing of an NDA for NCX 470 in China.
What does it mean ?
The positive regulatory feedback strengthens confidence in the approval pathway for NCX 470 and brings the product closer to commercialization, potentially generating milestone payments and royalties for Nicox.